274 related articles for article (PubMed ID: 25915913)
21. Peritoneal cancer patients not suitable for cytoreductive surgery and HIPEC during explorative surgery: risk factors, treatment options, and prognosis.
van Oudheusden TR; Braam HJ; Luyer MD; Wiezer MJ; van Ramshorst B; Nienhuijs SW; de Hingh IH
Ann Surg Oncol; 2015 Apr; 22(4):1236-42. PubMed ID: 25319584
[TBL] [Abstract][Full Text] [Related]
22. Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Dagbert F; Thievenaz R; Decullier E; Bakrin N; Cotte E; Rousset P; Vaudoyer D; Passot G; Glehen O
Ann Surg Oncol; 2016 Jun; 23(6):1980-5. PubMed ID: 26913716
[TBL] [Abstract][Full Text] [Related]
23. Failure to rescue following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Li KY; Mokdad AA; Minter RM; Mansour JC; Choti MA; Augustine MM; Polanco PM
J Surg Res; 2017 Jun; 214():209-215. PubMed ID: 28624046
[TBL] [Abstract][Full Text] [Related]
24. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with peritoneal hepatocellular carcinoma.
Tabrizian P; Franssen B; Jibara G; Sweeney R; Sarpel U; Schwartz M; Labow D
J Surg Oncol; 2014 Dec; 110(7):786-90. PubMed ID: 25091997
[TBL] [Abstract][Full Text] [Related]
25. Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin Increases the Risk of Postoperative Hemorrhagic Complications: Analysis of Predictive Factors.
Charrier T; Passot G; Peron J; Maurice C; Gocevska S; Quénet F; Eveno C; Pocard M; Goere D; Elias D; Ortega-Deballon P; Vaudoyer D; Cotte E; Glehen O
Ann Surg Oncol; 2016 Jul; 23(7):2315-22. PubMed ID: 26920385
[TBL] [Abstract][Full Text] [Related]
26. Re-admissions for delayed complications after cytoreductive surgery and HIPEC.
Spiliotis J; Argiriou EO; Vafias E; Manou V; Vaos N; Datsis A; Efstathiou E
Acta Chir Belg; 2016 Apr; 116(2):96-100. PubMed ID: 27385296
[TBL] [Abstract][Full Text] [Related]
27. Safety of gastric resections during cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis.
Piso P; Slowik P; Popp F; Dahlke MH; Glockzin G; Schlitt HJ
Ann Surg Oncol; 2009 Aug; 16(8):2188-94. PubMed ID: 19408049
[TBL] [Abstract][Full Text] [Related]
28. Genitourinary resection at the time of cytoreductive surgery and heated intraperitoneal chemotherapy for peritoneal carcinomatosis is not associated with increased morbidity or worsened oncologic outcomes: a case-matched study.
Leapman MS; Jibara G; Tabrizian P; Franssen B; Yang MJ; Romanoff A; Hall SJ; Palese M; Sarpel U; Hiotis S; Labow D
Ann Surg Oncol; 2014 Apr; 21(4):1153-8. PubMed ID: 24322531
[TBL] [Abstract][Full Text] [Related]
29. Extensive surgical history prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is associated with poor survival outcomes in patients with peritoneal mucinous carcinomatosis of appendiceal origin.
Milovanov V; Sardi A; Aydin N; Nieroda C; Sittig M; Nunez M; Gushchin V
Eur J Surg Oncol; 2015 Jul; 41(7):881-5. PubMed ID: 25899982
[TBL] [Abstract][Full Text] [Related]
30. Peritoneal metastases from small bowel cancer: Results of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in The Netherlands.
van Oudheusden TR; Lemmens VE; Braam HJ; van Ramshorst B; Meijerink J; te Velde EA; Mehta AM; Verwaal VJ; de Hingh IH
Surgery; 2015 Jun; 157(6):1023-7. PubMed ID: 25818658
[TBL] [Abstract][Full Text] [Related]
31. Hospital readmission rates and risk factors for readmission following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal surface malignancies.
Dreznik Y; Hoffman A; Hamburger T; Ben-Yaacov A; Dux Y; Jacoby H; Berger Y; Nissan A; Gutman M
Surgeon; 2018 Oct; 16(5):278-282. PubMed ID: 29429947
[TBL] [Abstract][Full Text] [Related]
32. Postoperative pancreatic fistula after cytoreductive surgery and perioperative intraperitoneal chemotherapy: incidence, risk factors, management, and clinical sequelae.
Saxena A; Chua TC; Yan TD; Morris DL
Ann Surg Oncol; 2010 May; 17(5):1302-10. PubMed ID: 20087784
[TBL] [Abstract][Full Text] [Related]
33. Does Intraoperative Systematic Bacterial Sampling During Complete Cytoreductive Surgery (CRS) with Hyperthermic Intraoperative Peritoneal Chemotherapy (HIPEC) Influence Postoperative Treatment? A New Predictive Factor for Postoperative Abdominal Infectious Complications.
Dazza M; Schwarz L; Coget J; Frebourg N; Wood G; Huet E; Bridoux V; Veber B; Tuech JJ
World J Surg; 2016 Dec; 40(12):3035-3043. PubMed ID: 27412631
[TBL] [Abstract][Full Text] [Related]
34. Morbidity and Mortality Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Data from the DGAV StuDoQ Registry with 2149 Consecutive Patients.
Piso P; Nedelcut SD; Rau B; Königsrainer A; Glockzin G; Ströhlein MA; Hörbelt R; Pelz J
Ann Surg Oncol; 2019 Jan; 26(1):148-154. PubMed ID: 30456672
[TBL] [Abstract][Full Text] [Related]
35. Predictive and prognostic survival factors in peritoneal carcinomatosis from appendiceal cancer after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.
Jimenez W; Sardi A; Nieroda C; Sittig M; Milovanov V; Nunez M; Aydin N; Gushchin V
Ann Surg Oncol; 2014 Dec; 21(13):4218-25. PubMed ID: 24986239
[TBL] [Abstract][Full Text] [Related]
36. Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
Lam JY; McConnell YJ; Rivard JD; Temple WJ; Mack LA
Am J Surg; 2015 Sep; 210(3):424-30. PubMed ID: 26051744
[TBL] [Abstract][Full Text] [Related]
37. Cytoreduction with hyperthermic intraperitoneal chemotherapy: an appraisal of outcomes and cost at a newly established peritoneal malignancy program.
Hinkle NM; MacDonald J; Sharpe JP; Dickson P; Deneve J; Munene G
Am J Surg; 2016 Sep; 212(3):413-8. PubMed ID: 27086201
[TBL] [Abstract][Full Text] [Related]
38. Perioperative Morbidity of Gastrectomy During CRS-HIPEC: An ACS-NSQIP Analysis.
Paredes AZ; Guzman-Pruneda FA; Abdel-Misih S; Hays J; Dillhoff ME; Pawlik TM; Cloyd JM
J Surg Res; 2019 Sep; 241():31-39. PubMed ID: 31004870
[TBL] [Abstract][Full Text] [Related]
39. The influence of transection site on the development of pancreatic fistula in patients undergoing distal pancreatectomy: A review of 294 consecutive cases.
Sell NM; Pucci MJ; Gabale S; Leiby BE; Rosato EL; Winter JM; Yeo CJ; Lavu H
Surgery; 2015 Jun; 157(6):1080-7. PubMed ID: 25791028
[TBL] [Abstract][Full Text] [Related]
40. Elevated Maximum Core Body Temperature During Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) is Associated with Increased Postoperative Complications.
Hendrix RJ; Kassira JP; Lambert LA
Ann Surg Oncol; 2020 Jan; 27(1):232-239. PubMed ID: 31286314
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
